CSNK2B (Casein kinase II subunit beta) — Review notes

UniProt: P67870 (CSK2B_HUMAN); HGNC:2460; gene CSNK2B; 215 aa; chr 6p21.33 (MHC class III region).

Core biology

CSNK2B is the regulatory beta subunit of protein kinase CK2 (casein kinase 2), a
constitutively active, highly pleiotropic acidophilic Ser/Thr kinase. The CK2 holoenzyme is a
heterotetramer: two catalytic subunits (CSNK2A1/alpha and/or CSNK2A2/alpha') bridged by a
CSNK2B beta dimer (alpha2beta2). CSNK2B itself has no catalytic activity; it dimerizes via a
zinc-finger (Zn-binding residues Cys109, Cys114, Cys137, Cys140 — [file:human/CSNK2B/CSNK2B-uniprot.txt]),
docks the two catalytic subunits, stabilizes the holoenzyme, raises basal catalytic activity, and
modulates substrate specificity/selectivity, sometimes recruiting substrates directly
PMID:11574463.

CK2 consensus is S/T-X-X-D/E (acidic at +3) and the enzyme phosphorylates hundreds of substrates,
affecting transcription, translation, cell-cycle, DNA repair, Wnt and other signaling, apoptosis
(major recognized role: counteracting apoptosis), and circadian rhythm
PMID:28031292.

CK2beta is required for assembly, stability and substrate selection of the holoenzyme, and also has
roles independent of CK2 enzymatic activity including negative regulation of cell proliferation
PMID:19324893.

Structure / domains

• Zinc-finger-mediated homodimerization; crystal structures 1QF8 (reg subunit), 1JWH (holoenzyme with CSNK2A1).
  PMID:11574463
• C-terminal region 188–193 contacts the alpha subunit.
• KSSR motif (residues 147–150) forms a protein-interaction pocket mediating binding to cellular
  and viral partners (ARK2N/ARKL1, EBV EBNA1). KSSR->AAAA abolishes ARK2N and EBNA1 binding but not
  CSNK2A1 binding [PMID:24216761 (UniProt MUTAGEN annotation); file:human/CSNK2B/CSNK2B-uniprot.txt].

Substrate-recruitment / adaptor functions (CK2beta as docking/scaffold)

CK2beta mediates interactions of the holoenzyme with specific substrates and can redirect CK2 toward
specific substrates PMID:20719947.

Specific examples:
- p53 Ser392 phosphorylation: CK2 forms a CK2–SPT16–SSRP1 (FACT) complex after UV; CK2beta mediates
assembly [UniProt SUBUNIT; PMID:11239457/12393879 cited in UniProt].
- MuSK: CK2-dependent phosphorylation regulates AChR aggregation at the NMJ; CK2beta interacts with MuSK
[PMID:16818610 cited in UniProt FUNCTION].
- PRH/HHEX (HHEX homeodomain): CK2beta binds PRH (Y2H + cells) and CK2 phosphorylates PRH homeodomain
(S163/S177), acting as a reversible switch inhibiting PRH DNA binding and transcriptional regulation
PMID:19324893. Source of the GO:0061629 (transcription-factor binding) and GO:0008285 (neg reg
proliferation) annotations.
- HSJ1/DNAJB2: CK2 phosphorylates the UIM2 (Ser250 dominant, Ser247 hierarchical), reducing HSJ1 binding
to ubiquitylated clients and chaperone activity; CK2 inhibition enhances HSJ1 client binding — i.e. CK2
negatively regulates proteasomal degradation of HSJ1 clients (GO:0032435)
PMID:28031292.
- ALK1/ACVRL1 signaling: CK2beta binds ALK-1 cytoplasmic domain (res 181–199 of CK2beta), enhancing
Smad1/5/8 phosphorylation and ALK-1 reporter activity in response to TGF-beta1/BMP-9, and antagonizing
endothelial cell migration and tubule formation. siRNA of CK2beta reduces Smad1/5/8 signaling. Basis for
GO:0060391, GO:0032927, GO:0005102 (ACVRL1/P37023 binding), GO:0043537, GO:0061154
PMID:19592636.
- AdipoR1/adiponectin signaling: CK2 (regulatory subunit) binds AdipoR1 N-terminus (Y2H, co-IP, co-loc);
CK2 inhibitor DMAT modulates adiponectin signaling. Basis for GO:0005102 (AdipoR1/Q96A54), GO:0005737,
GO:0005886, GO:0033211 PMID:19233263.

Viral / PML

• EBV EBNA1 binds CK2 directly via CK2beta (KSSR pocket), increasing CK2 occupancy at PML bodies and PML
  phosphorylation (S517), triggering PML polyubiquitylation/degradation — disruption of host PML nuclear
  bodies. Basis for GO:0016605 (PML body, is_active_in), GO:0075342 [PMID:20719947, PMID:24216761].
• ARKL1/ARK2N: CK2beta mediates ARKL1–c-Jun interaction; silencing CK2beta (not CK2alpha) phenocopies ARKL1
  silencing and promotes EBV reactivation — CK2beta is needed for ARKL1's repression of Zp/BZLF1 (negative
  regulation of viral life cycle). Basis for GO:1903901, GO:0030674 (adaptor activity bridging ARK2N–Jun),
  GO:0000785 (chromatin is_active_in at Zp). PMID:31341047.

Polycomb / chromatin

• CK2 (CSNK2A/B) is a bona fide component of a subset of non-canonical PRC1 complexes (PRC1-AUTS2 / PCGF
  variants). In PRC1-AUTS2, the CK2 component phosphorylates RING1B and neutralizes PRC1 repressive
  activity, converting it to an activating complex; AUTS2 recruits P300
  PMID:25519132.
• CSNK2B co-purifies with PcG/CBX proteins and RING1B/RNF2 [PMID:21282530; PMID:22325352; PMID:27705803].
  ComplexPortal/NAS annotations assign CSNK2B to PRC1 complex (GO:0035102), chromatin (GO:0000785),
  heterochromatin formation (GO:0031507) and positive regulation of transcription (GO:0045893) on this
  basis. These are complex-membership / process transfers driven by the broader PRC1-AUTS2 complex;
  CSNK2B's direct contribution is its kinase-regulatory role within the embedded CK2.

Localization

• Nucleus (EXP, IDA: PMID:31341047, PMID:21282530); nucleoplasm/fibrillar center (HPA IDA); cytoplasm and
  plasma-membrane co-localization in adiponectin signaling context (PMID:19233263). CK2 is broadly
  cytosolic and nuclear. Reactome assigns cytosol/nucleoplasm. "Extracellular region", "secretory granule
  lumen", "ficolin-1-rich granule lumen", "extracellular exosome" are bulk-secretome/neutrophil-degranulation
  transfers (Reactome TAS, HDA) — not the core localization of an intracellular kinase subunit.

Disease

• Poirier-Bienvenu neurodevelopmental syndrome (POBINDS; MIM 618732): autosomal dominant, seizures in
  infancy, developmental delay, intellectual disability; de novo / splice-site / missense variants;
  haploinsufficiency mechanism [PMID:28585349; PMID:31784560; PMID:36833176].

Interactome (mostly high-throughput Y2H/AP-MS GO:0005515 "protein binding")

The bulk of GO:0005515 IPI annotations are from large-scale interactome / AP-MS / Y2H screens (e.g.
PMID:32296183, 33961781, 35271311, 32707033, 21988832, 23555304, 40205054, 26496610, etc.). The
biologically central, repeatedly recovered partners are the CK2 catalytic subunits CSNK2A1 (P68400) and
CSNK2A2 (P19784) and CSNK2B itself (homodimer, identical protein binding GO:0042802). Many other partners
(RPS6KA3/RSK2, RNF2, SIRT1, etc.) are reported but "protein binding" is uninformative as a function term.

Summary of curation stance

• Core MF: protein kinase regulator activity (GO:0019887) within the CK2 holoenzyme; molecular adaptor /
  scaffold (GO:0030674) recruiting substrates/partners. CSNK2B does NOT itself have kinase activity, so
  GO:0004674 enables/contributes_to annotations are problematic (see below).
• Core CC: protein kinase CK2 complex (GO:0005956).
• Direct biological role best captured as protein phosphorylation (the holoenzyme activity it regulates);
  most downstream BP terms (Wnt, transcription, circadian, viral, SMAD, etc.) are substrate-driven
  pleiotropy and are non-core.
• The GO:0004674 "protein serine/threonine kinase activity" annotations: with contributes_to qualifier
  (PMID:28031292, PMID:1856204) this is the accepted way to annotate a non-catalytic subunit of an active
  kinase complex (the subunit contributes to the complex's activity) — ACCEPT/KEEP. The single enables
  GO:0004674 IDA (PMID:15723517) is misleading because CSNK2B does not enable kinase activity on its own;
  better is contributes_to / the regulator term — MODIFY.